The present invention provides a sea cucumber genital gland extract, preferably, a novel saponin compound separated from an ovary extract, and a novel use of a sea cucumber genital gland extract or a compound separated from a sea cucumber genital gland extract. The present invention has an effect of treating or preventing any one or more diseases selected from the group consisting of obesity, inflammation, diabetes and dyslipidemia, by comprising a sea cucumber genital gland, preferably, an ovary extract, or a compound separated from a sea cucumber genital gland, preferably, an ovary extract.

The invention refers to a method for obtaining polyhydroxy 1,4-naphthoquinones from live sea urchins, comprising the following steps: a) injecting a KCl saline solution into the perivisceral coeloma of female sea urchins to induce spawning; b) collecting the eggs, and grinding them into a fine powder; c) mixing said fine powder with an alcoholic solvent; d) separating the alcohol supernatant comprising the polyhydroxy 1,4-naphthoquinones in solution.
Where the polyhydroxy 1,4-naphthoquinones are selected from: echinochrome A (6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone), spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthoquinone), spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthoquinone), spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone), spinochrome D (2,3,5,6,8-pentahydroxy-1,4-naphthoquinone), spinochrome E (hexahydroxy-1,4-naphthoquinone) or mixtures thereof.

A method of processing whole fresh shellfish, including whole live bivalves, and the resulting compositions in liquid and dried form having a high yield of bioactive components with improved bioavailability. The method includes an enzyme treatment step of applying an enzyme formulation having one or more enzymes to the shellfish, and leaving the shellfish in contact with the enzyme formulation until the flesh and other biological material is substantially separated from the shells or exoskeletons of the shellfish, and liquefying the flesh and biological material using of the same enzyme formulation in the same enzyme treatment step, and/or by applying a different enzyme formulation in the same or one or more subsequent enzyme treatment steps. In a preferred method the shellfish starting material is live at the application of the enzyme. The method does not use mechanical processes to reduce the size of the shellfish before application of the enzyme.

The present invention relates to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract as an active ingredient, and more particularly, to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract having effects of regenerating the Bruch's membrane of an eye and improving a transport function. The composition according to the present invention improves the transport function of the Bruch's membrane and promotes the regeneration of the Bruch's membrane, thereby delaying or reversing an eye aging process, and thus has excellent effects on the prevention and treatment of a disease such as age-related macular degeneration (AMD), Sorsby's fundus dystrophy, Malattia Levintanese (ML), Stargardt disease, Best's vitelliform retinal dystrophy and Doyne's honeycomb retinal dystrophy (DHRD), which occurs due to the age-related dysfunction of the Bruch's membrane.

The present invention relates to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract as an active ingredient, and more particularly, to a composition for preventing and treating a Bruch's membrane dysfunction-associated disease, which includes a sea cucumber extract having effects of regenerating the Bruch's membrane of an eye and improving a transport function. The composition according to the present invention improves the transport function of the Bruch's membrane and promotes the regeneration of the Bruch's membrane, thereby delaying or reversing an eye aging process, and thus has excellent effects on the prevention and treatment of a disease such as age-related macular degeneration (AMD), Sorsby's fundus dystrophy, Malattia Levintanese (ML), Stargardt disease, Best's vitelliform retinal dystrophy and Doyne's honeycomb retinal dystrophy (DHRD), which occurs due to the age-related dysfunction of the Bruch's membrane.

A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.

A method is provided for preparing an ECM material, including an ECM gel, from regenerative or regenerating tissue. ECM material prepared from regenerative or regenerating materials also is provided.

A composition that includes at least two of: echinochrome A (2-ethyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone); spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthalenedione); spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthalenedione); spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthalenedione); spinochrome D (2,3,5,6,8-Pentahydroxy-1,4-naphthalenedione); and spinochrome E (hexahydroxy-1,4-naphthalenedione). The composition can include one or more additional active ingredients (e.g., vitamin, tretinoin (alltrans retinoic acid or ATRA), a glycosaminoglycan (GAG), dermal filler, Botulinum toxin, etc.) and/or one or more inactive ingredients (e.g., solvent, carrier, gelling agent, coloring agent, etc.). The composition can be in a dry, solid form (e.g., powder), or in a liquid form. Additionally, each of the above components above can independently be present in the composition in either the naturally derived form, or in a synthetically prepared form.

A composition that includes at least two of: echinochrome A (2-ethyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone); spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthalenedione); spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthalenedione); spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthalenedione); spinochrome D (2,3,5,6,8-Pentahydroxy-1,4-naphthalenedione); and spinochrome E (hexahydroxy-1,4-naphthalenedione). The composition can include one or more additional active ingredients (e.g., vitamin, tretinoin (alltrans retinoic acid or ATRA), a glycosaminoglycan (GAG), dermal filler, Botulinum toxin, etc.) and/or one or more inactive ingredients (e.g., solvent, carrier, gelling agent, coloring agent, etc.). The composition can be in a dry, solid form (e.g., powder), or in a liquid form. Additionally, each of the above components above can independently be present in the composition in either the naturally derived form, or in a synthetically prepared form.

The present invention relates to a sea urchin-derived peptide and a use thereof and more specifically, to a use of the sea urchin-derived peptide for preventing or treating a disease associated with the V1B receptor of Echinotocin, which is a peptide derived from sea urchins. The Echinotocin according to the present invention was found to have an effect of inducing activation of the V1B receptor, which is a type of vasopressin receptors. The V1B receptor, which is a vasopressin receptor, exists in the anterior pituitary gland and the hippocampus CA2 region and is known to increase intracellular calcium concentration and to be involved in a response to stress and sociality. Therefore, the Echinotocin according to the present invention can find various applications in the field of preventing, alleviating, or treating V1B receptor-related diseases.